JP2023531390A5 - - Google Patents
Info
- Publication number
- JP2023531390A5 JP2023531390A5 JP2022576009A JP2022576009A JP2023531390A5 JP 2023531390 A5 JP2023531390 A5 JP 2023531390A5 JP 2022576009 A JP2022576009 A JP 2022576009A JP 2022576009 A JP2022576009 A JP 2022576009A JP 2023531390 A5 JP2023531390 A5 JP 2023531390A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- acceptable salt
- cycloalkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025277389A JP2026053536A (ja) | 2020-06-12 | 2025-12-23 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010536221 | 2020-06-12 | ||
| CN202010536221.6 | 2020-06-12 | ||
| CN202011147078.8 | 2020-10-23 | ||
| CN202011147078 | 2020-10-23 | ||
| CN202011261665 | 2020-11-12 | ||
| CN202011261665.X | 2020-11-12 | ||
| CN202110485680 | 2021-04-30 | ||
| CN202110485680.0 | 2021-04-30 | ||
| CN202110614030.1 | 2021-06-02 | ||
| CN202110614030 | 2021-06-02 | ||
| PCT/CN2021/099654 WO2021249534A1 (zh) | 2020-06-12 | 2021-06-11 | 酞嗪酮类化合物及其制备方法和医药用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025277389A Division JP2026053536A (ja) | 2020-06-12 | 2025-12-23 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531390A JP2023531390A (ja) | 2023-07-24 |
| JP2023531390A5 true JP2023531390A5 (cg-RX-API-DMAC7.html) | 2024-06-19 |
| JP7797421B2 JP7797421B2 (ja) | 2026-01-13 |
Family
ID=78846889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576009A Active JP7797421B2 (ja) | 2020-06-12 | 2021-06-11 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
| JP2025277389A Pending JP2026053536A (ja) | 2020-06-12 | 2025-12-23 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025277389A Pending JP2026053536A (ja) | 2020-06-12 | 2025-12-23 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
Country Status (18)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| AU2020414151A1 (en) | 2019-12-23 | 2022-08-25 | Jiangxi Jemincare Group Co., Ltd | Protein degradation agent compound preparation method and application |
| CA3174353A1 (en) * | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Compounds and methods for modulating splicing |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| KR20230024328A (ko) | 2020-06-12 | 2023-02-20 | 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 | 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도 |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| KR102474999B1 (ko) * | 2021-05-26 | 2022-12-07 | 주식회사 이노큐어테라퓨틱스 | 피페리딘디온 유도체 |
| JP2024519628A (ja) * | 2021-05-26 | 2024-05-21 | イノキュア セラピューティクス インコーポレイテッド | ピペリジンジオン誘導体 |
| WO2023016518A1 (zh) | 2021-08-11 | 2023-02-16 | 四川海思科制药有限公司 | 一种杂环衍生物及其组合物和药学上的应用 |
| US20260159520A1 (en) * | 2022-09-08 | 2026-06-11 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2024054952A1 (en) * | 2022-09-08 | 2024-03-14 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| JP2025538554A (ja) * | 2022-11-22 | 2025-11-28 | イノキュア セラピューティクス,インコーポレイテッド | Brdタンパク質を分解するための分解剤およびそれを含有する薬学的組成物 |
| EP4624472A1 (en) * | 2022-11-22 | 2025-10-01 | Innocure Therapeutics, Inc. | Degrader including novel c-met protein ligand and pharmaceutical composition including same |
| EP4624466A1 (en) * | 2022-11-22 | 2025-10-01 | Innocure Therapeutics, Inc. | Degrader for decomposing cmet protein, and pharmaceutical composition comprising same |
| CN116655591B (zh) * | 2023-06-05 | 2024-11-08 | 中国人民解放军军事科学院军事医学研究院 | 3,4-二氢酞嗪-1(2h)-酮类衍生物及制备方法和用途 |
| EP4763845A1 (en) | 2023-08-17 | 2026-06-24 | Haisco Pharmaceutical Group Co., Ltd. | Cyano aromatic ring derivative and pharmaceutical use thereof |
| EP4780815A1 (en) | 2023-09-20 | 2026-07-29 | Aurigene Oncology Limited | Heterocyclic compounds as cbp selective degraders |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025108406A1 (zh) * | 2023-11-22 | 2025-05-30 | 广东东阳光药业股份有限公司 | 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途 |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| TW202600539A (zh) | 2024-03-13 | 2026-01-01 | 美商建南德克公司 | Ar降解劑之多形體 |
| WO2025193851A1 (en) | 2024-03-13 | 2025-09-18 | Genentech, Inc. | Process for making enantiomers of ar-degraders |
| WO2025226797A1 (en) | 2024-04-24 | 2025-10-30 | Genentech, Inc. | Kred catalyzed ketoreduction of a cyclobutanone carbamic ester |
| US12169941B1 (en) | 2024-06-13 | 2024-12-17 | Rapsodo Pte. Ltd. | System and method for determining a position an object crosses a target plane |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245804B1 (en) * | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| DE19723722A1 (de) * | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| SI3526202T1 (sl) * | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| US10842878B2 (en) | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| AU2017363257B2 (en) | 2016-11-22 | 2021-08-19 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| CN110194762B (zh) * | 2018-02-27 | 2021-09-10 | 中国科学院上海药物研究所 | 酞嗪酮类衍生物、其制备方法和用途 |
| CN112390852B (zh) | 2019-08-14 | 2022-10-18 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的化合物及其制备方法和应用 |
| CN112457367B (zh) | 2019-09-06 | 2022-08-23 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的连环类化合物及其制备方法和应用 |
| CN118085015A (zh) | 2019-09-06 | 2024-05-28 | 江西济民可信集团有限公司 | 作为蛋白降解剂的并环类化合物及其制备方法和用途 |
| CN112574278B (zh) | 2019-09-29 | 2024-08-23 | 江西济民可信集团有限公司 | 作为蛋白降解剂杂环类化合物及其制备方法和医药应用 |
| AU2020414151A1 (en) | 2019-12-23 | 2022-08-25 | Jiangxi Jemincare Group Co., Ltd | Protein degradation agent compound preparation method and application |
| CN113582974B (zh) | 2020-04-30 | 2022-05-17 | 江西济民可信集团有限公司 | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 |
| KR20230024328A (ko) | 2020-06-12 | 2023-02-20 | 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 | 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도 |
-
2021
- 2021-06-11 KR KR1020237000214A patent/KR20230024328A/ko active Pending
- 2021-06-11 TW TW110121476A patent/TWI781651B/zh active
- 2021-06-11 MX MX2022015562A patent/MX2022015562A/es unknown
- 2021-06-11 CN CN202110653817.9A patent/CN113801098B/zh active Active
- 2021-06-11 BR BR112022025057A patent/BR112022025057A2/pt unknown
- 2021-06-11 PH PH1/2023/550018A patent/PH12023550018A1/en unknown
- 2021-06-11 PE PE2022002889A patent/PE20230610A1/es unknown
- 2021-06-11 AU AU2021286738A patent/AU2021286738A1/en active Pending
- 2021-06-11 CR CR20230007A patent/CR20230007A/es unknown
- 2021-06-11 IL IL298962A patent/IL298962A/en unknown
- 2021-06-11 EP EP21822688.4A patent/EP4166550A4/en active Pending
- 2021-06-11 JP JP2022576009A patent/JP7797421B2/ja active Active
- 2021-06-11 CN CN202310167758.3A patent/CN116082311B/zh active Active
- 2021-06-11 WO PCT/CN2021/099654 patent/WO2021249534A1/zh not_active Ceased
- 2021-06-11 CA CA3186981A patent/CA3186981A1/en active Pending
-
2022
- 2022-12-07 CL CL2022003472A patent/CL2022003472A1/es unknown
- 2022-12-07 CO CONC2022/0017802A patent/CO2022017802A2/es unknown
- 2022-12-12 SA SA522441725A patent/SA522441725B1/ar unknown
- 2022-12-12 US US18/079,778 patent/US20230131252A1/en active Pending
-
2023
- 2023-04-05 US US18/131,309 patent/US11767312B2/en active Active
-
2024
- 2024-08-14 US US18/804,443 patent/US12234223B2/en active Active
-
2025
- 2025-12-23 JP JP2025277389A patent/JP2026053536A/ja active Pending